110
- Jones JL, Kaplan GG, Peyrin-Biroulet L, et al. Effects of concomitant immunomodulator therapy
on efficacy and safety of anti-tumor necrosis factor therapy for Crohn’s disease: a meta- analysis
of placebo-controlled trials. Clin Gastroenterol Hepatol. 2015;13:2233–40.e1-2; quiz e177-8. - D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional
management in patients with newly diagnosed Crohn’s disease: an open randomised trial.
Lancet. 2008;371:660–7. - Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the
management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet.
2015;386:1825–34. - Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in
patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36. - Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regi-
mens for moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2009;104:2524–33. - Deepak P, Stobaugh DJ, Ehrenpreis ED. Infectious complications of TNF-alpha inhibitor
monotherapy versus combination therapy with immunomodulators in inflammatory bowel
disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
J Gastrointestin Liver Dis. 2013;22:269–76. - Dulai PS, Thompson KD, Blunt HB, et al. Risks of serious infection or lymphoma with anti-
tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Clin Gastroenterol Hepatol. 2014;12:1443–51; quiz e88-9. - Kopylov U, Afif W. Risk of infections with biological agents. Gastroenterol Clin N Am.
2014;43:509–24. - Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with
Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol.
2012;107:1409–22. - Brassard P, Bitton A, Suissa A, et al. Oral corticosteroids and the risk of serious infections in
patients with elderly-onset inflammatory bowel diseases. Am J Gastroenterol. 2014;109:1795–
802; quiz 1803. - Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe
infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory
bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5. - Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated
with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis.
2013;7:107–12. - Buckley JP, Cook SF, Allen JK, et al. Prevalence of chronic narcotic use among children with
inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;13(2):310–5. - Buckley JP, Kappelman MD, Allen JK, et al. The burden of comedication among patients with
inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2725–36. - Long MD, Barnes EL, Herfarth HH, et al. Narcotic use for inflammatory bowel disease and
risk factors during hospitalization. Inflamm Bowel Dis. 2012;18:869–76. - Long MD, Martin C, Sandler RS, et al. Increased risk of pneumonia among patients with
inflammatory bowel disease. Am J Gastroenterol. 2013;108:240–8. - Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the preven-
tion, diagnosis and management of opportunistic infections in inflammatory bowel disease.
J Crohns Colitis. 2014;8:443–68. - Loras C, Saro C, Gonzalez-Huix F, et al. Prevalence and factors related to hepatitis B and
C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am
J Gastroenterol. 2009;104:57–63. - Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepati-
tis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther.
2011;33:619–33. - Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated
with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205–10.
P.S. Dulai and C.A. Siegel